Flamma

What Flamma does

Flamma S.p.A. is a privately held, family-owned Contract Development and Manufacturing Organization (CDMO) founded in 1950 in Bergamo, Italy, that specializes in the development and cGMP manufacture of small molecule active pharmaceutical ingredients (APIs), new chemical entities (NCEs), registered starting materials (RSMs), and key intermediates. The company serves pharmaceutical innovator companies and biotech firms, delivering services from pre-clinical development through commercial-scale production under a quote-based, project-by-project pricing model with multi-year contracts (Net 30 terms). Confirmed enterprise customers include Gilead Sciences, for which Flamma manufactured Veklury (remdesivir) from sites in Italy and China.

The technology platform spans high-containment HPAPI manufacturing (OEB 4 isolators rated at 1 µg/m³ for genotoxic materials), cryogenic API manufacturing (down to -50°C), continuous flow chemistry (Corning G4 Microreactor and Microinnova modular systems capable of 16 bar, 145°C, up to 50 MT/year), and crystallization / solid-state services (in-house plus a cooperation with Seven Star Pharmaceutical Services). Quality by Design (QbD) methodology is applied systematically. Operations are distributed across seven sites — Chignolo d'Isola (HQ, Italy), Isso (Italy), Bulciago (Italy, acquired from Teva in 2022), Dalian/Honkai (China, 100% owned), Malvern (USA, acquired from Teva in 2019), Boston (USA sales), and Paris (France sales) — delivering ~1,500 m³ of total reactor capacity and over 700 employees supporting an estimated 1,000 families.

The commercial model is enterprise-led direct sales through regional offices in Boston and Paris plus relationship-driven outreach at major industry events (CPhI Worldwide, DCAT, CDMO LIVE Americas), reinforced by a generic API portfolio (MelaPure™ melatonin, Minoxidil, Methacholine Chloride, Phosphoserine, amino acid derivatives) and trademarked sub-brands. The company has announced $200–$250M of investment over three years for capacity expansion and technology upgrades, including a tripling of China capacity to 600 m³ and the 2025 grand opening of a new cGMP plant at Flamma Honkai. Flamma remains 100% family-controlled across three generations of the Negrisoli family with no outside institutional investment, and has received multiple CDMO Leadership Awards, including recognition as the only small-molecule CDMO rated a Top Performer in all 6 core and 7 specialty categories out of 110 CDMOs evaluated.

Name

Flamma

Legal name

Flamma S.p.A.

Website

https://flammagroup.com

Company type

Private

Founded year

1950

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Flamma is a privately held, family-owned CDMO founded in 1950 that develops and manufactures small molecule APIs, NCEs, and intermediates under cGMP across sites in Italy, China, the USA, and France, serving pharmaceutical innovator and biotech customers through custom development and contract manufacturing services.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Pharmaceutical CDMO services
• Small molecule API manufacturing
• Contract development manufacturing
• CGMP API production
• HPAPI manufacturing

Headquarters

HQ city

Bergamo

HQ country

Italy

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing (CDMO Services): Flamma provides cGMP manufacturing of small molecule APIs, NCEs, RSMs, and key intermediates for pharmaceutical companies. Services include process development, custom synthesis, scale-up, analytical validation, regulatory support, and commercial manufacturing from pre-clinical through commercial phases.
2. Generic API and Product Sales: Flamma produces and sells a portfolio of generic APIs including Melatonin (MelaPure), Minoxidil, Arginine-L-Aspartate, Methacholine Chloride, and Phosphoserine. Also produces amino acid derivatives, Fmoc-amino acids, protected amino acids, and intermediates.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Flamma is a family-owned pharmaceutical CDMO that provides cGMP manufacturing of small molecule Active Pharmaceutical Ingredients (APIs), New Chemical Entities (NCEs), Registered Starting Materials (RSMs), and Key Intermediates for pharmaceutical innovator companies. Services span custom process development, custom synthesis, scale-up, analytical validation, regulatory support, and commercial manufacturing from pre-clinical through commercial phases across FDA, AIFA, and NMPA inspected facilities in Italy, China, and the USA.

Product overview

Flamma is a family-owned, privately held CDMO founded in 1950 that provides end-to-end pharmaceutical development and manufacturing services. The company operates as a single integrated platform offering custom manufacturing, custom development, and cGMP manufacturing services across its global network. Its product portfolio includes generic APIs (MelaPure™ melatonin, Minoxidil, and Phosphoserine), Registered Starting Materials (RSMs), New Chemical Entities (NCEs), and advanced intermediates including specialized amino acid derivatives. Key technology capabilities include HPAPI manufacturing, continuous flow chemistry, cryogenic API manufacturing, and crystallization research. Flamma leverages these capabilities to serve pharmaceutical customers from early-stage pre-clinical development through commercial-scale manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• MelaPure™: Pharmaceutical grade melatonin brand, marketed as the purest form of melatonin in the industry.
• CarnoPure™
• Flamma Honkai
• Flamma USA

Products and services

• Custom Manufacturing Process validation, analytical validation, commercial manufacturing from kilos to metric tons under cGMP conditions, and regulatory support including QA/QC for pharmaceutical customers.
• Custom Development Process development and optimization, custom synthesis and route scouting, scale-up capabilities, and analytical validation and development for pharmaceutical customers from pre-clinical through commercial phases.
• cGMP Manufacturing Current Good Manufacturing Practice (cGMP) manufacturing services for APIs, New Chemical Entities (NCEs), Registered Starting Materials (RSMs) and Key Intermediates across multiple regulatory jurisdictions.
• Highly Potent API (HPAPI) Manufacturing Specialized manufacturing service for Highly Potent Active Pharmaceutical Ingredients with OEB 4 high-containment facilities capable of handling compounds with OEL > 0.1 µg/m3, including genotoxic materials.
• Continuous Flow Chemistry Continuous flow chemistry manufacturing service using Corning G4 Microreactor and Microinnova modular systems enabling higher pressures, improved selectivity and safety with reduced footprint, supporting green processes with recycling.
• Cryogenic API Manufacturing Low temperature API manufacturing service for specialized reactions requiring cryogenic conditions down to -50°C.
• Crystallization Research (Solid State) Solid state science services including salt and co-crystal selection, crystallization development, polymorph investigation, and pre-formulation evaluation delivered through internal capabilities and a cooperative agreement with Seven Star Pharmaceutical Services.
• Generic APIs Portfolio of small molecule generic APIs including Acetyl DL-Leucine, Arginine-L-Aspartate, Melatonin (MelaPure), Methacholine Chloride, Minoxidil, and Phosphoserine sold to pharmaceutical customers.
• MelaPure (Melatonin) Pharmaceutical grade melatonin (CAS 73-31-4) marketed under the MelaPure trademark as the purest form of melatonin in the industry.
• Amino Acid Derivatives High-value amino acid derivatives including Fmoc-amino acids, Boc-amino acids, Cbz-amino acids, and specialty protected amino acids used for peptide synthesis, drawing on Flamma's 75-year amino acid heritage.

Quantifiable outcome

• Time-to-market reduction from 12 to 6 years realized using QbD approach
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Seven Star Pharmaceutical ServicescoreStrategic or Co-development Partner · 15 August 2024Cooperative agreement to expand Flamma's solid state science services. The collaboration enables identification of proper API versions through salt & co-crystal selection, crystallization development, polymorph investigation, and pre-formulation evaluation. Seven Star's proximity to Flamma USA coupled with their expertise benefits existing and new customers.
• Italy China Council Foundation (ICCF)minorOthers · 14 December 2023ICCF recognized Flamma as a Top Investor in China at the China Awards event, honoring companies for cross-economic activity between Italy and China.
• CorningcoreTechnology or Integration · 19 September 2023Installation of a Corning G4 Microreactor for continuous flow production. The technology enables work at higher pressures, improved selectivity and safety with reduced footprint, and supports green processes with recycling.
• MicroinnovacoreTechnology or Integration · 19 July 2023Investment of ~$2M in modular continuous flow systems from Microinnova, a leader in modular Continuous Flow systems. The 'partially modular' system allows exchange of reactor modules as needed, increasing flexibility for different products and reaction requirements.
• VIPCAT Project ConsortiumminorStrategic or Co-development Partner · 30 September 2019Flamma participates in the VIPCAT project developing new approaches through chemical and enzymatic synthesis for preparation of aroma and fragrances and APIs with high atom economy and green process. Flamma implements this technology on its Generic APIs using continuous flow chemistry and solid state techniques.
• European Fine Chemical Group (EFCG)minorOthersFlamma is a proud member of the European Fine Chemical Group.

Scale indicators10 records

Recent moves11 records

Expansion highlights7 records

Direct peers

• Hovione: Portugal-based privately held CDMO specializing in small molecule API development and manufacturing, including HPAPI and particle engineering. Closest privately-held European analog to Flamma in scale, ownership structure, and service mix.
• AGC Pharma Chemicals: Japan-headquartered API CDMO with European manufacturing (formerly Bayer/SiChem). Comparable to Flamma in small molecule custom synthesis, HPAPI capability, and global customer base.
• Cambrex: US/Europe-headquartered small molecule API CDMO acquired by Permira in 2019 for ~$2.4B. Very close comparable to Flamma in offering mix (small molecule APIs, intermediates, HPAPI) and customer base of pharma innovators.
• Seqens (formerly PCAS): France-based specialty ingredients and API CDMO with cGMP manufacturing sites. Comparable to Flamma on European-headquartered small molecule API CDMO services and HPAPI/high-containment capabilities.
• Sai Life Sciences: India-based CDMO providing contract development and manufacturing services for small molecule APIs. Comparable to Flamma on integrated discovery-to-commercial API services and active entry into HPAPI and complex chemistry.
• EuroAPI: French API manufacturer spun out from Sanofi in 2022, offering small molecule APIs and intermediates. Comparable to Flamma on European-based small molecule API manufacturing and supply to global pharma companies.
• Laurus Labs: India-headquartered CDMO/API manufacturer with significant scale in small molecule APIs and intermediates. Comparable to Flamma on contract manufacturing service model and pharma innovator customer base, particularly for cost-competitive programs.
• WuXi STA (WuXi AppTec): Chinese subsidiary of WuXi AppTec, a major global small molecule API CDMO. Direct competitor on contract API development and manufacturing scale, including continuous flow and HPAPI capabilities.
• Siegfried Holding AG: Swiss-headquartered small molecule API and drug product CDMO with global manufacturing footprint. Directly comparable to Flamma on API CDMO services and was a fellow nominee in the 2025 CDMO Leadership Awards Best On-Time Delivery category.
• Piramal Pharma Solutions: India-headquartered CDMO offering API development and manufacturing across North America, Europe and Asia. Comparable to Flamma on integrated development-to-commercial services and HPAPI capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/flammagroup
• Facebookfacebook.com/TheFlammaGroup
• LinkedInlinkedin.com/company/flamma-spa

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flamma